Treatment of hereditary angioneurotic oedema (HANE) with tibolone.
Clin Endocrinol (Oxf)
; 66(2): 180-4, 2007 Feb.
Article
en En
| MEDLINE
| ID: mdl-17223985
ABSTRACT
OBJECTIVE:
Eight women, aged 25-58 years, with hereditary angioneurotic oedema (HANE) were treated with tibolone, a synthetic steroid exhibiting oestrogenic, androgenic and progestational activity.DESIGN:
Pilot study.RESULTS:
Tibolone at a dose of 2.5-7.5 mg/day significantly reduced the number and severity of attacks and the number of ampoules of C1-esterase inhibitor (C1-INH) needed for symptomatic therapy. The efficacy of tibolone was comparable to that of danazol, while the androgenic side-effects were considerably reduced.CONCLUSIONS:
Tibolone may represent an alternative to danazol administration for the prophylaxis of HANE in women.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Angioedema
/
Norpregnenos
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Clin Endocrinol (Oxf)
Año:
2007
Tipo del documento:
Article
País de afiliación:
Austria